SRRK vs PLXS Comparison

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.